CagriSema News & Analysis

Novo Nordisk (NVO) Stock Target Set at $47 by Goldman Sachs

Goldman Sachs has maintained its Neutral rating and $47 price target on Novo Nordisk (NVO) after meeting with the management at the 47th Annual Global Healthcare Conference on June 9. This target represents a 7% upside from the closing price of 287.25 Danish kroner on June 12, which was up 1.66% for the day. Earlier this year, Novo shares dropped to a 52-week low near $37 following disappointing trial results for its drug CagriSema. Additionally, it held a 39% market share in the U.S. obesity and diabetes GLP-1 market, compared to Eli Lilly’s 60%.